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Abstract
Patients with inflammatory bowel disease (IBD) have an 
increased risk of 10%-15% developing colorectal cancer 
(CRC) that is a common disease of high economic 
costs in developed countries. The CRC has been 
increasing in recent years and its mortality rates are 
very high. Multiple biological and biochemical factors 
are responsible for the onset and progression of this 
pathology. Moreover, it appears absolutely necessary 
to investigate the environmental factors favoring the 
onset of CRC and the promotion of colonic health. The 
gut microflora, or microbiota, has an extensive diversity 
both quantitatively and qualitatively. In utero , the 
intestine of the mammalian fetus is sterile. At birth, the 
intestinal microbiota is acquired by ingesting maternal 
anal or vaginal organisms, ultimately developing into a 
stable community, with marked variations in microbial 
composition between individuals. The development 
of IBD is often associated with qualitative and 
quantitative disorders of the intestinal microbial flora 
(dysbiosis). The healthy human gut harbours about 
10 different bacterial species distributed in colony 
forming units which colonize the gastrointestinal tract. 
The intestinal microbiota plays a fundamental role 
in health and in the progression of diseases such as 
IBD and CRC. In healthy subjects, the main control 
of intestinal bacterial colonization occurs through 
gastric acidity but other factors such as endoluminal 
temperature, competition between different bacterial 
strains, peristalsis and drugs can influence the 
intestinal microenvironment. The microbiota exerts 
diverse physiological functions to include: growth 
inhibition of pathogenic microorganisms, synthesis of 
compounds useful for the trophism of colonic mucosa, 
regulation of intestinal lymphoid tissue and synthesis 
of amino acids. Furthermore, mucus seems to play an 
important role in protecting the intestinal mucosa and 
maintaining its integrity. Changes in the microbiota 
composition are mainly influenced by diet and age, as 
well as genetic factors. Increasing evidence indicates 
that dysbiosis favors the production of genotoxins 
and metabolites associated with carcinogenesis and 
induces dysregulation of the immune response which 
promotes and sustains inflammation in IBD leading 
to carcinogenesis. A disequilibrium in gut microflora 
composition leads to the specific activation of gut 
associated lymphoid tissue. The associated chronic 
inflammatory process associated increases the risk of 
developing CRC. Ulcerative colitis and Crohn’s disease 
are the two major IBDs characterized by an early onset 
and extraintestinal manifestations, such as rheumatoid 
arthritis. The pathogenesis of both diseases is complex 
and not yet fully known. However, it is widely accepted 
that an inappropriate immune response to microbial 
flora can play a pivotal role in IBD pathogenesis.
© 2014 Baishideng Publishing Group Inc. All rights reserved.
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Core tip: Dysbiosis could be the common denominator 
of inflammatory bowel disease (IBD) and colorectal 
cancer. A well balanced gut microbiota promotes the 
health of colocytes through the production of important 
compounds and the correct modulation of immune 
system. Qualitative and quantitative modifications in 
the bacterial composition are responsible of changes 
in the biochemistry and in the cell cycle of colocytes. 
The aim of this work is to focus on the molecular 
mechanisms that connect dysbiosis, IBD and colorectal 
cancer. Experimental studies are oriented towards 
the discovery of new probiotic-based therapies for 
the treatment and prevention of inflammatory and 
carcinogenetic processes.
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INTRODUCTION
Inflammatory bowel diseases (IBD), such as Crohn’s 
disease (CD) and Ulcerative colitis (UC), are pathologies 
characterized by a chronic inf lammation of  the 
gastrointestinal tract. In UC, rectal and descending 
colon involvement is a typical feature whereas CD 
can affect any part of  the gastrointestinal tract from 
the mouth to the anus. Their aetiopathogenesis is not 
yet fully understood[1,2]. It is now well established that 
close interactions exist between the luminal bacterial 
flora and the intestinal immune cells and tissues. Such 
interactions are involved in the onset and progression 
of  several diseases including IBDs and colorectal 
cancer (CRCs)[3-7]. Dysbiosis of  gut microflora may 
represent the “primum movens” of  the chronic 
inflammation characterizing IBD and triggering the 
stimulation of  the immune system[8-13]. Dismicrobism 
can cause alterations in the immune response and 
can, in particular, lead to gut associated lymphoid 
tissue (GALT) activation[14]. The terms dysbiosis and 
dismicrobism are being used interchangeably, however, 
dismicrobism is sometimes more used in reference to 
the condition evolving consequent to the administration 
of  antibiotics. Specifically, the microbiological imbalance 
(dysbiosis) causes to a modification of  intercellular 
tight junctions[15] leading to an effective penetration of  
antigens responsible of  the activation of  GALT with 
consequent tissue damage[16]. Olsen and Co-workers 
tested the reactivity of  intestinal T cells derived from 
patients with CD, UC and undetermined colitis against 
some bacteria. The results showed that T lymphocytes 
isolated from CD patients had a high reactivity against 
Mycobacterium avium compared to patients affected by UC 
and undetermined colitis. Moreover, the isolated T cells 
produced inflammatory cytokines like interferon (IFN)-γ 
and IL-17[17]. These data suggest a possible involvement 
of  Mycobacteria in CD immunopathology. Other 
bacteria belonging to Clostridia group, Fusobacterium, 
Mycobacterium, adherent invasive Escherichia coli (E. coli), 
Proteus mirabilis, Klebsiella pneumonia and Proteobacteria such 
as Helicobacter spp were found over-represented in the 
IBD condition[18,19]. Nowadays several studies focus on 
the possibility to control IBD through the modulation 
of  the immune system by re-establishment of  eubiosis 
through specific probiotic mixtures. The homeostasis 
of  the immune system is very important and involves 
the equilibrium between pro-inflammatory and anti-
inflammatory cytokines such as IL-10 and others. Mgl1-/- 
mice with a DSS induced colitis were studied before and 
after probiotic treatment. The induction of  colitis in wild 
type mice showed a less severe phenotype compared 
to Mgl1-/- mice and a lowered expression of  IL-10 in 
the mutant mice, leading to the evidence that Mgl1 is 
involved in the regulation of  IL-10 production. The 
results showed that Lactobacillus and Streptococcus were 
able to bind to Mgl1 receptor, leading to the hypothesis 
that these bacterial strains may be able to induce an anti-
inflammatory response[20]. These findings highlight the 
importance of  gut microbiota both in the triggering 
and in the modulation of  immune system in the chronic 
inflammatory diseases of  the gastrointestinal tract.
Diagnosis of dysbiosis
There is a relatively wide spectrum of  diagnostic tests used 
for the diagnosis of  dysbiosis. They cover all four patterns 
of  dysbiosis by analysis of  both stool and urine for 
respective markers. Reference laboratories specializing in 
the evaluation of  dysbiosis offer a comprehensive testing 
of  various aspects of  digestion, absorption, microbiology, 
metabolic markers and immunology including fetal 
secretory IgA and sometimes calprotectin. In addition, in 
some cases of  medical necessity, fecal analysis may also 
include other standard components such as stool culture, 
stool parasitology and fecal occult blood[21,22].
Tomasello G et al . Eubiosis and dysbiosis in IBD
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ETIOLOGICAL LINK DYSIOSIS TO IBD 
AND CRC
The etiology of  IBD is linked to three basic parameters: 
(1) genetic predisposition; (2) a dysregulated immune 
response; and (3) an altered reaction to gut microorganisms. 
It is also well established that the mechanism of  intestinal 
inflammation, acute or chronic, involves a complex 
myriad of  pathogens (bacteria, viruses or fungi), 
chemicals, radiation, dietary components and hormones 
among others[1,11,23]. It also involves another complex 
series interactions between immune cells (T cells B 
cells, NK cells, mast cells, macrophages), interleukins, 
bradykinins, complement system factors, prostaglandins, 
tumour necrosis factors, histamines, hormones and 
activated neutrophils products like myeloperxidase, 
radicals and oxydants[1,23]. In some cases, the body’
s reaction is not enough to rid itself  from etiological 
agents and infecting organisms. The reaction persists as 
a chronic inflammation which proliferates into multiple 
complications, escalating the damage, especially in 
genetically susceptible individuals. The big question 
is how could this chronic inflammation progress and 
express itself, and how could its complications lead to 
the formation of  cancerous cells? It is well documented 
that patients with this condition are more prone to the 
development of  malignancy and that the microbiota 
could sustain the chronicity of  the inflammatory state in 
the presence of  a dysregulated immune response[3,6]. Such 
a persistent inflammation is believed to play a significant 
role in CRC development[24-26]. Studies in this field 
reported underlying genetic, proteomic, and epigenetic 
changes in IBD’s and CRC’s. Individuals with IBD have 
mostly permissive rather than causative genes[23].
In CD, an early discovery on chromosome 16 (IBD 
1 gene) led to the identification of  3 single nucleotide 
polymorphisms (2 missense, 1 frameshift) in the NOD2 
gene (now called CARD 15 is a polymorphic gene 
involved in the innate immune system and has more than 
60 variations, of  which 3 play a role in 27% of  patients 
with CD, primarily in patients with ileal disease. Another 
early genome-wide association study looked at Jewish and 
non-Jewish case-control cohorts and identified 2 single 
nucleotide polymorphisms in the lL23R gene, which 
encode 1 subunit of  the interleukin-23 receptor protein. 
Actually, 21 new loci were identified with an increased 
risk of  developing CD such as the genes CCR6, IL 
12B, STAT3, JAK2, LRRK2, CDKAL 1, and PTPN22. 
Most of  these genes are involved in signal transduction 
in immune function. There is also a strong support for 
IBD-susceptibility genes on chromosome 5p131.1 which 
is a gene desert but does modulate expression of  the 
PTGER4 gene. A murine PTGER4 knockout model has 
also a significant susceptibility to severe colitis[26,27].
In UC, however, the genetic predisposition is less 
than that of  CD. Actually, there is a set of  genetic 
susceptibilities that show significant overlap with 
CD. A recent genome-wide association study found a 
previously unknown susceptibility locus at ECM1 and 
showed several common risk loci between UC and CD. 
Genes that are a risk of  both diseases appear to have an 
influence on the immune environment of  the intestine[28].
Further susceptibility loci for UC have been 
found on 1p36 and 12q15. The lp36 single nucleotide 
polymorphism is located near the PLA2G2E gene; 
involved in releasing arachidonic acid from membrane 
phospholipids, which leads to other pro-inflammatory 
lipids. The first 12q15 signal is located near the interferon 
(IFN)-γ, interleukin (IL)-26, and IL-22 genes, whereas the 
second 12q15 signal is located in IL-26. These genes have 
roles in the immune response to pathogens as well as the 
tissue inflammation processes. It was also shown that 
genetic predisposition increases the risk for one form of  
IBD while decreasing that of  the other[27].
Chlorinated adducts of  DNA and RNA, which 
are generated from reaction with MPO products, are 
associated with repetitive infiltration of  neutrophils and 
macrophages to the site of  inflammation. Furthermore, 
these chlorination products increased in amount as the 
inflammatory state lengthened. Importantly, infiltration 
by these innate immune cells was accompanied by cancer 
initiation and progression. Actually, the contributing 
factors to the onset of  colon carcinoma were infiltration 
of  phagocytes and macromolecular damage to DNA 
and RNA (chlorination) mediated by neutrophil activity. 
In cases of  UC, IL-8, Cl-Tyr, SAA, CRP, procalcitonin, 
G-CSF, and tissue plasminogen activator have been 
identified, whereas for CD cases, procalcitonin, SAA, 
Nitro-Tyr, and IP-10 were identified as the most 
influential factors[23]. 
Albumin is the most abundant chlorinated species 
found in serum; it is synthesized and released in the 
liver, indicating the liver as a possible site for innate 
cell activation in IBD patients, and therefore a possible 
source of  the chlorination and nitration products 
observed in serum. This finding suggests that 5-CI-dC 
may be a contributing factor in the initiation of  colon 
carcinogenesis through either mutational or gene silencing 
mechanisms. In addition, two interesting proteins were 
identified from a proteomics study: Orosomucoid 2 
(“-1-acid glycoprotein 2) and Peptidylglycan recognition 
protein 2 (PGRP2, also named N-acetylmuramoyl-L-
alanine amidase). Association of  orosmucoid 2 with UC 
disease activity was not established, but it was associated 
with development of  colorectal cancer[23].
Concerning colorectal cancer, it has been reported 
for several decades that carcinomas mostly develop from 
adenomas and chronic inflammations. In 1988, Vogelstein 
described four specific mutations that accumulate during 
the progression of  adenomas to carcinomas. These 
mutations seem to involve gatekeeper genes, which 
enable genetic or epigenetic instability and support tumor 
growth[29].
Various factors have been shown to be responsible 
for the accumulation of  mutations in CRC including 
inheritance and environmental factors (e.g., composition 
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microbes in healthy and diseased individuals. A strong 
and well documented correlation exists between the 
composition of  the gut microbiota and diet. In general, 
dietary change could explain most of  the total structural 
variation in gut microbiota in metabolic syndrome 
repeats[35].
Such microbial changes in the GI tract have profound 
effects on host inflammatory and metabolic responses. 
So far, it is not known for sure whether diet-induced 
dysbiosis is a transient or long-term event[38]. This is a 
very dynamic area of  research since dietary choices are 
proven to modify the ecology of  intestinal microbiota 
which could increase susceptibility to disease like, IBD 
and CRC.
Dysbiosis in CRC
The next-generation sequencing and taxonomic studies, 
based on ribosomal 16S bacterial genes, give a clearer 
picture of  the microorganisms inhabiting our intestine 
in physiological and pathological conditions, although a 
healthy core microbiota has not been clearly identified. 
The microbiota analysis on tissues and fecal materials 
has identified various microbial groups associated with 
CRC. Stool samples derived from CRC patients harbour 
a higher population of  bacteria belonging to the group 
Bacteroides-Prevotella compared with normal controls[24]. 
Another study showed an enrichment in the luminal 
compartment of  CRC patients compared to controls 
of  bacteria belonging to Enterococcus, Escherichia, Shigella, 
Klebsiella, Streptococcus, and Peptostreptococcus, and a depletion 
of  bacteria belonging to Lachnospiraceae family (butyrate-
producing bacteria)[25,39]. CRC is a multi-step process that 
includes adenoma formation. Studies of  microbiota on 
intermediate stages revealed an increased abundance of  
Firmicutes, Bacteroidetes, and Proteobacteria at the intestinal 
mucosal surface in patients with adenoma compared with 
non-adenoma subjects[34]. Moreover, resected tissues from 
adenocarcinoma patients and adjacent non-malignant 
sites showed expansion of  the phyla Bacteroidetes and 
reduction of  Firmicutes in tumors compared with 
healthy subjects[4]. Interestingly, through whole-genome 
and RNA-sequencing approaches two independent 
groups found a high prevalence of  Fusobacterium (over-
represented also in IBD) in colonic tissues of  CRC 
patients compared with normal controls[40,41].
Modulation of immune response in IBD
The intestinal microbiota is involved in aetiopathogenesis 
of  autoimmune and allergic diseases and can also play a 
role in the development of  CRC[6]. Many cancers arise 
from sites of  infection and chronic inflammation. The 
strongest association of  chronic inflammation with 
malignant diseases is found in inflammatory bowel 
diseases of  the colon with a lifetime incidence of  10% 
or more. Thus, patients with IBD have a higher risk of  
CRC occurrence[1,42]. Both innate and adaptive immune 
responses have been involved in the pathogenesis 
of  IBD. The first one involves particular receptors 
of  diet, obesity, diabetes mellitus, smoking, alcohol 
consumption) as well, besides the fact that chronic 
inflammation sustained by microbial flora is regarded as 
an important risk factor for the development of  cancer[30].
On the other hand, IL-6 is regarded as an important 
tumor promoting factor in many types of  human cancer 
including glioma, lymphoma, melanoma as well as 
breast, ovarian, pancreatic, prostate, renal and, colorectal 
cancer[29,31].
Various studies have found an increased expression of  
lL-6 in patients with CRC, where lL-6 levels are elevated 
in the serum of  patients and in tumor tissue itself. 
According to a review article by Knupfer and Preiss, 
lL-6 expression can be associated with tumor stage, size, 
metastasis and survival of  patients with CRC[32]. 
Many studies have revealed that lL-6 is an important 
regulator of  IBD pathogenesis, mainly through its effect 
on immune cell function in the gut. lL-6 trans-signalling 
has been shown to activate T cells in the lamina propria 
of  patients with IBD and induces resistance of  these 
cells against apoptosis through upregulation of  anti-
apoptotic factors such as Bcl-2 and Bcl-xl. IL-6 is deemed 
to act as a link between chronic inflammation and tumor 
development due to its increased expression in IBD 
patients[29]. 
Dysbiosis and diet
There is a myriad of  factors, in addition to intestinal 
microbiota, that play a crucial role in the development of  
IBD and CRC. An altered microbiota, termed dysbiosis, 
could lead to altered immune functions and increased risk 
of  disease[33]. The influence of  diet on the composition 
of  the microbiota has been well documented during the 
initial colonization phase, postnatally and beyond, even 
in adult life[34]. Several studies demonstrated that dietary 
factors have a dominating role in altering the microbial 
community resulting in biological changes to the host. 
Actually dietary changes could explain 57% of  the total 
structural variation whereas genetic factors accounted 
for less than 12%[35]. For example, the “Western” diet, 
which is high in sugar and fat, causes dysbiosis affecting 
both gastrointestinal (GI) metabolism and immune 
homeostasis[30]. Vegetarianism, which is high in fibbers, 
results in increased short chain fatty acid production 
by microbes leading to a decrease in intestinal pH and 
consequently preventing the growth of  potentially 
pathogenic bacteria such as E.coli and members of  
the Enterobacteriaceae[36]. In brief, it is becoming well 
documented that the microbiota could be modified 
through dietary factors to enrich beneficial microbes and 
prevent diseases associated with dysbiosis or promote 
such diseases like; IBDs metabolic diseases like diabetes, 
obesity as well as irritable bowel syndrome, celiac disease 
and also CRC. Diet-induced dysbiosis affects disease 
susceptibility[37].
Understanding how extrinsic factors such as diet 
alter disease susceptibility through modification in 
the microbiota could shed light onto the function of  
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called Toll like receptors or PRR (Pattern recognition 
receptors). It has been considered as an impairment of  
the innate immune response rather than an excessive 
activation, which may be involved in the development of  
CD. In fact some genes such as NOD2 (an intracellular 
PRR involved in the recognition of  the bacterial muramyl 
dipeptide) showed mutations consisting in a loss rather 
than a gain of  function[43]. Regarding the adaptive 
immune response, IBD is characterized by dysregulated 
T lymphocyte effector cells, and shows a Th1 and Th17 
activation to the endogenous microbiota, and a lack of  
immune suppression typically afforded by Tregs[44]. CD 
is considered a disease with an increased Th1 response 
while UC is a Th2-mediated disease. This paradigm 
relies on evidence showing that intestinal tissues derived 
from patients with active CD contain elevated levels of  
IL-12 and IL-18 (Th1-polarizing cytokines), compared 
with UC patients[45,46]. Moreover, in CD patients, an 
increased amount of  Th1 lymphocytes has been reported 
compared to control subjects[45]. Evidence from studies 
conducted on humans and animal models suggest that 
the different subsets of  lymphocytes play their role in 
different stages of  IBDs[43]. Studies of  CD pathogenesis 
in SAMP1/YitFc mice indicate an involvement of  
Th1 cells in the initiation process of  the disease. The 
establishment of  chronic inflammation is supported by 
IL-5 and IL-13 cytokines, indicating a role of  Th2 subset 
in this stage of  CD[47]. These data indicate that adaptive 
immune responses involved in IBD pathogenesis are 
more complex than the traditionally dichotomous Th1/
Th2 paradigm (Figure 1).
Modulation of immune response in CRC
About 1%-2% of  CRC patients have a pathological 
background consisting of  intestinal mucosa inflammation[48]. 
This “inflammatory background” of  colonic mucosa can 
evolve to a less (low-grade) or more severe (high-grade) 
dysplasia, which through neoplastic transformation 
gives rise to carcinoma “in situ” and finally “invasive” 
carcinoma. Interestingly, many lines of  evidence 
highlighted the importance of  intestinal microbiota in 
the development of  CRC[42] and that the type of  immune 
response generated by the gut commensal bacteria could 
potentially influence tumor immunity[49]. Mice colonized 
with enterotoxigenic B. Fragilis exhibit colonic Th17 
inflammatory infiltrates that are involved in induction 
of  colon tumors, as indicated by inhibition of  colon 
tumor formation following treatment with anti-IL-17 
antibody[50]. It is, therefore, possible that a microbiota 
favouring commensal bacteria, that induces a Th17 
response, could have differential effects on tumors 
depending on the type of  tumor or the stage of  tumor 
development[49]. The amount of  lymphocytes infiltrated 
in the tumoral tissue is correlated to the prognosis of  the 
patients affected by CRC[51]. Among the different subsets 
of  T lymphocytes studied in the immune system is the 
γδ population. This lymphocytic subset is characterized 
by the presence of  γδ chains in their TCR and their 
representation in peripheral blood is < 10%. Since γδ T 
cells express both natural killer receptors (NKG2D) and 
γδ T cell receptors, they are considered as a link between 
innate and adaptive immunity[52]. CRC comprises a small 
population of  cancer stem cells (CSC) responsible for 
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Figure 1  One hypothesis on the initiation of the inflammatory process in inflammatory bowel disease bases on an abnormal Th1 response mediated by 
the secretion of interferon gamma and tumor necrosis factor-a while the chronic inflammation is supported by interleukin-5 and interleukin-13 secreted by 
Th2 cells. IFN: Interferon; TNF: Tumor necrosis factor; IL: Interleukin; IBD: Inflammatory bowel disease.
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tumor resistance to therapies. It has been observed that 
the treatment with the bisphosphonate zoledronate 
sensitizes colon CSCs to γ9δ2 T cell cytotoxicity through 
the production of  pro-inflammatory cytokines [IFN γ and 
tumor necrosis factor (TNF)-a] and granule exocytosis 
pathway. The γδ T cells response is highly dependent on 
isoprenoid production by tumor cells[53]. Isoprenoids are 
a class of  natural compounds derived from five-carbon 
isoprene units assembled and modified in different 
ways. Most of  them have multicyclic structures found 
in all classes of  living organisms such as bacteria. These 
compounds are under investigation for their involvement 
in bacterial metabolism and immunomodulation of  γ9δ2 
T lymphocytes. Isoprenoids are synthesized through 
the mevalonate pathway or the alternative 2C-methyl-
D-erythritol 4-phosphate (MEP) pathway. It has been 
observed that the MEP intermediate pathway 1-hydroxy-
2-methyl-2-(E)-butenyl 4-diphosphate (HMB-PP) can 
activate human γ9δ2 T cells. Some pathogen bacteria 
such as Campylobacter jejuni and Salmonella enterica have 
genes involved in the MEP pathway. Since HMB-PP and 
other isoprenoids are able to induce activation of  γ9δ2 T 
cells, this metabolic feature shared by bacteria and host 
cells should be used to fight together dysbiosis and the 
tumorigenesis process of  CRC.
Modulation of Heat shock proteins by gut microflora
The “chaperoning system” is a concept that was proposed 
in 2008[54]. Heat shock proteins (Hsps) are cellular 
complexes involved in processes like folding, refolding, 
translocation and degradation of  intracellular proteins 
under normal and stress conditions[6,55]. Hsp chaperones 
are also involved in many cellular processes and interact 
with the immune system. They start to be considered 
as potential biomarkers of  carcinogenesis, correlating 
their expression to the degree of  differentiation and 
aggressiveness of  certain tumors. Pathological conditions 
in which chaperones become etiological factors are 
called “chaperonopathies” and are classified into three 
cathegories: by defect, by excess, and by mistake[56]. 
Commensal microbiota may affect the immune system 
influencing the expression of  specific Hsps. In particular, 
Hsp60 and Hsp70, both constitute a group of  auto-
antigens able to trigger immune-regulatory pathways, 
involved also in other human inflammatory processes 
such as rheumatoid arthritis[57], Type 1 diabetes mellitus[58], 
atherosclerosis[59] and allergy[60], through the stimulation 
of  both innate and adaptive immune responses[61]. These 
proteins were found increased in both tissue and serum 
of  patients with UC[7]. The microbiota is able to regulate 
Hsp expression. Studies conducted on patients affected 
by IBD showed a decrease of  Hsp60, Hsp10 and Hsp70 
in epithelium and lamina propria after a combined 
therapy of  5- amino salicylic acid plus probiotics 
(Lactobacillus Salivarius, Lactobacillus Acidophilus, and 
Bifidobacterium Bifidum)[62]. Treatment of  gut epithelial 
cells with Lactobacillus GG showed an increase in Hsp25 
and Hsp72 (considered as cytoprotective Hsps) in a time 
and concentration dependent manner. These data suggest 
that the microbiota is able to influence Hsps expression 
in colocytes.
Double role of microbiota: Prevention or promotion of 
carcinogenesis
Gut microflora has a great importance; it influences 
the colonocyte’s life under multiple aspects. In certain 
groups of  individuals, the onset of  CRC is strongly 
related to diet and composition of  the microbiota[42]. 
The aforementioned correlation could be explained 
through the anticancer effects of  bioproducts of  
microflora metabolism[63]. Small-chain fatty acids 
(SCFAs), particularly butyrate, formed from the bacterial 
fermentation of  indigestible carbohydrates, are nutrients 
and growth signals for the intestinal epithelium and may 
play a role in CRC prevention[64]. In normal colonocytes, 
butyrate prevents apoptosis and subsequent mucosal 
atrophy[10,65]. In contrast, in colon carcinoma cells, 
butyrate exerts a protective role against the onset of  
colonic cancer stimulating differentiation, inhibiting 
cell proliferation, inducing apoptosis and inhibiting 
angiogenesis[66]. The role of  butyrate resides in its effects 
on enzymatic functions such as the inhibition of  the 
histone deacetylase. This enzyme is responsible of  the 
maintenance of  the acetylated state of  the histones. 
Acetylation is important for the access to the chromatin 
by the enzymes responsible of  the transcription of  
important genes such as those involved in the inhibition 
of  tumorigenesis (p21/Waf1)[67]. Inhibition of  histone 
deacethyltransferases enzymes (HDAC) is one of  the 
therapeutic approaches used in anticancer therapy. 
Microbial metabolism of  cruciferous vegetables or 
garlic leads to the production of  compounds such 
as sulforaphane N-acetyl-cysteine, allyl mercaptan 
and butyrate. Thus, microbe-derived metabolites can 
counteract the carcinogenetic process by triggering 
cell cycle arrest and apoptosis of  tumoral cells through 
interference with HDAC activity [10,68]. Endoluminal 
accumulation of  toxic compounds can exert a mutagenic 
action on intestinal mucosa. The microbial fermentation 
of  charred meat leads to the production of  poli-
heterocyclyc amines (PAH). These compounds are able 
to damage the DNA of  colonocytes. Bacteria belonging 
to the Clostridium species are able to convert the bile acids 
into secondary products like deoxycholic acid (DCA). 
This compound is capable to induce the carcinogenesis 
process[69]. Tumorigenesis is a multi-step process in which 
the damage in the DNA is the essential pre-condition 
for tumoral induction. E. coli has a genic cluster called 
Pks that encodes for a toxin called calibactin. This was 
illustrated in studies conducted in mice which are not 
able to produce IL-10. They were treated either with 
one strain of  E. coli in which Pks was deleted and the 
others with the wild type strain. The results of  this 
experiment showed that the genic cluster Pks was only 
able to induce damage on the DNA (assessed trough the 
presence of  H2AX marker) but not sufficient to induce 
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rectal carcinogenesis[65,70]. Experimental data show that 
consumption of  omega-3 polyunsaturated fatty acids 
is able to decrease the incidence of  sporadic colorectal 
cancer. Eicosapentaenoic free fatty acid reduces polyp 
formation and growth in models of  familial adenomatous 
polyposis[71]. The intake of  docosahexaenoic acid can 
modify the gut microflora. Breast milk is rich in omega-3 
fatty acids. Some studies showed that Bifidobacteria are 
more represented in breastfed infants rather than in 
formula-fed infants. In another study, it was shown that 
the supplementation with fish oil is able to determine 
changes in Bacteriodetes among children 9-18 mo old[72]. 
An understanding of  the comprehension of  the correct 
equilibrium in the prevalence of  the different bacterial 
strains composing human microbiota may represent 
one of  the keys for the better understanding of  CRC 
etiopathogenesis. In fact, bacterial metabolism has a high 
impact on the biochemistry of  colocytes (Figure 2). This 
field of  study may open the road to therapies oriented 
not only towards specific probiotic-based therapies but 
also to targeted “prebiotic-based” approaches for the 
prevention or treatment of  CRC. 
CONCLUSION
The role of  environmental factors involved in CRC 
aetiopathogenesis remains to be fully elucidated. 
The qualitative and quantitative modifications of  the 
microbiota can make people more susceptible to develop 
IBD. In fact, these changes can trigger the production 
of  inflammatory mediators in the mucosa that, in a large 
temporal window, can also exert a pro-cancerogenic role. 
The immunological and biochemical evidences related 
to dysbiosis allow the global comprehension of  the 
background on which relies the development of  CRC 
(Figure 3). These findings suggest a close connection 
between dysbiosis, IBD and CRC. Up till now, the direct 
or indirect role of  bacteria in the induction of  genomic 
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Eubiosis
Protection against inflammatory processes and 
physiologic mucosa permeability
Production of metabolites useful for the 
trophism of colocytes
Induction of cytoprotective Hsp
Dysbiosis
Promotion of inflammatory processes and 
increase of mucosa permeability (IBD)
Production of procarcinogenic 
compounds (CCR)
Release of Hsp that trigger immune 
system response
Figure 2  Eubiosis and dysbiosis exert different biochemical effects in the context of colocytes pathophysiology. IBD: Inflammatory bowel disease.
Eubiosis Dysbiosis
SCFA
Enhancement of 
barrier function
Firmicutes
Damage of barrier 
function
Fusobacterium nucleatum
E. coli
Colorectal cancer
Inhibition of the inflammatory process by Treg cells
Immune regulation
Treg cell Th17 cell
Inflammation and DNA damage in 
colocytes
Dysregulation of immune response
Treg cell Th17 cell
Figure 3  At eubiosis stage, the intestinal epithelium hosts a rich and equilibrated microbiota that promotes the barrier function. Microbial dysbiosis 
favors the production of genotoxins and metabolites associated with carcinogenesis. Moreover dysbiosis induces dysregulation of immune responses that cause 
inflammation promotion of carcinogenesis. SCFA: Small-chain fatty acids; E. coli: Escherichia coli.
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damages in colocytes is not fully comfirmed. Several 
clinical trials have focused the preventive and therapeutic 
action of  probiotics in the treatment of  digestive 
diseases. Probiotics could inhibit the inflammatory and 
the carcinogenetic processes through several pathways 
including the re-equilibration of  the host immune 
responses and through the anti-proliferative activity 
on tumor cells. However, further clinical studies seem 
necessary to clarify the complex interplay between 
dysbiosis, inflammation and CRC. 
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